Division of Neuroscience, New England Primate Research Center, Harvard Medical School, Southborough, MA 01772, United States.
Pharmacol Biochem Behav. 2012 Apr;101(2):201-7. doi: 10.1016/j.pbb.2011.10.025. Epub 2011 Nov 4.
The trace amine-associated receptor 1 (TAAR1) is a G protein-coupled receptor that is functionally activated by amphetamine-based psychostimulants, including amphetamine, methamphetamine and MDMA. Previous studies have shown that in transgenic mice lacking the TAAR1 gene (TAAR1 knockout; KO) a single injection of amphetamine can produce enhanced behavioral responses compared to responses evoked in wild-type (WT) mice. Further, the psychostimulant effects of cocaine can be diminished by selective activation of TAAR1. These findings suggest that TAAR1 might be implicated in the rewarding properties of psychostimulants. To investigate the role of TAAR1 in the rewarding effects of drugs of abuse, the psychomotor stimulating effects of amphetamine and methamphetamine and the conditioned rewarding effects of methamphetamine and morphine were compared between WT and TAAR1 KO mice. In locomotor activity studies, both single and repeated exposure to d-amphetamine or methamphetamine generated significantly higher levels of total distance traveled in TAAR1 KO mice compared to WT mice. In conditioned place preference (CPP) studies, TAAR1 KO mice acquired methamphetamine-induced CPP earlier than WT mice and retained CPP longer during extinction training. In morphine-induced CPP, both WT and KO genotypes displayed similar levels of CPP. Results from locomotor activity studies suggest that TAAR1 may have a modulatory role in the behavioral sensitization to amphetamine-based psychostimulants. That methamphetamine-but not morphine-induced CPP was augmented in TAAR1 KO mice suggests a selective role of TAAR1 in the conditioned reinforcing effects of methamphetamine. Collectively, these findings provide support for a regulatory role of TAAR1 in methamphetamine signaling.
痕量胺相关受体 1(TAAR1)是一种 G 蛋白偶联受体,可被安非他命类精神兴奋剂(包括安非他命、甲基苯丙胺和 MDMA)功能激活。先前的研究表明,在缺乏 TAAR1 基因(TAAR1 敲除;KO)的转基因小鼠中,单次注射安非他命与野生型(WT)小鼠相比,可产生增强的行为反应。此外,选择性激活 TAAR1 可以减弱可卡因的精神兴奋剂作用。这些发现表明 TAAR1 可能与精神兴奋剂的奖赏特性有关。为了研究 TAAR1 在滥用药物奖赏效应中的作用,比较了 WT 和 TAAR1 KO 小鼠中安非他命和甲基苯丙胺的精神运动刺激效应以及甲基苯丙胺和吗啡的条件奖赏效应。在运动活性研究中,单次和重复暴露于 d-安非他命或甲基苯丙胺均可使 TAAR1 KO 小鼠的总行进距离显著高于 WT 小鼠。在条件位置偏好(CPP)研究中,TAAR1 KO 小鼠比 WT 小鼠更早地获得了甲基苯丙胺诱导的 CPP,并且在消退训练期间保持 CPP 的时间更长。在吗啡诱导的 CPP 中,WT 和 KO 基因型均显示出相似的 CPP 水平。运动活性研究的结果表明,TAAR1 可能在基于安非他命的精神兴奋剂的行为敏化中具有调节作用。在 TAAR1 KO 小鼠中,甲基苯丙胺而非吗啡诱导的 CPP 增强,这表明 TAAR1 在甲基苯丙胺的条件强化效应中具有选择性作用。总的来说,这些发现为 TAAR1 在甲基苯丙胺信号传导中的调节作用提供了支持。